{"preliminary_commentary":{"by_channel":{"x_thread":9,"podcast":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04262856\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["domvanalimab","zimberelimab"],["domvanalimab","zimberelimab","etrumadenant"],["zimberelimab"]],"indication":"front-line PD-L1 positive non-small cell lung cancer","name":"ARC-7","nct_id":"NCT04262856","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=arc-7-nct04262856. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ARC-7","arms":[{"description":"Participants will receive zimberelimab as an intravenous (IV) infusion.","label":"Arm 1 (zimberelimab monotherapy)","type":"EXPERIMENTAL"},{"description":"Participants will receive domvanalimab IV in combination with zimberelimab IV infusion.","label":"Arm 2 (domvanalimab and zimberelimab combination therapy)","type":"EXPERIMENTAL"},{"description":"Participants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion","label":"Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)","type":"EXPERIMENTAL"}],"collaborators":["Gilead Sciences"],"completion_date":{"date":"2025-07-09","type":"ACTUAL"},"conditions":["Non Small Cell Lung Cancer","Nonsquamous Non Small Cell Lung Cancer","Squamous Non Small Cell Lung Cancer","Lung Cancer"],"enrollment":{"count":151,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Domvanalimab","otherNames":["AB154"],"type":"DRUG"},{"name":"Etrumadenant","otherNames":["AB928"],"type":"DRUG"},{"name":"Zimberelimab","otherNames":["AB122"],"type":"DRUG"}],"last_update":"2026-06-15","lead_sponsor":"Arcus Biosciences, Inc.","official_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-07-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective response rate (ORR)","timeFrame":"From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)"},{"measure":"Progression-free survival (PFS)","timeFrame":"From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)"}],"references":[],"start_date":{"date":"2020-05-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04262856"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/arc-7-nct04262856"}